|
| Home : Targovax announces that the ONCOS-102 and durvalumab trial successfully completes part 1 in colorectal cancer |
|
Oct 13
2020 |
Targovax announces that the ONCOS-102 and durvalumab trial successfully completes part 1 in colorectal cancer |
|
OSLO, Norway, Oct. 13, 2020 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announced that the colorectal cancer cohort in part 1 of the ONCOS-102 and durvalumab trial in colorectal... |
|
|
|
| Source:https://www.prnewswire.com:443/news-releases/targovax-announces-that-the-oncos-102-and-durvalumab-trial-successfully-completes-part-1-in-colorectal-cancer-301150766.html |
| |
|
Related News
|
» Gerresheimer on track for strong second half-year
» Nestlé announces results of tender offer for Aimmune Therapeutics, Inc.
|
|
|
